What Is Vesugen?
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson specifically targeting vascular endothelial tissue. It is a fully synthetic peptide with high specificity for endothelial cells, designed to restore normal vascular cell gene expression and support angiogenesis — the formation of new blood vessels — in aging or ischemia-damaged tissue. It complements Ventfort's broader vascular coverage by focusing on endothelial cell biology specifically. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Endothelial-Specific Focus
The endothelium — the single cell layer lining all blood vessels — regulates vascular tone through nitric oxide and prostacyclin production, maintains anticoagulant properties of the vessel wall, mediates inflammatory cell recruitment, and governs angiogenesis through VEGF and angiopoietin signaling. Vesugen is designed to restore normal endothelial cell gene expression across all these functions.
Research Applications
Vesugen has been studied for peripheral vascular disease, ischemic heart disease, wound healing in the context of poor vascularity, and as an anti-aging vascular restoration agent. Animal studies document increased endothelial cell density in ischemic tissue, improved capillary density, enhanced eNOS expression and nitric oxide production, and faster recovery of blood flow following ischemic challenge in treated animals. Russian clinical research documents improvements in peripheral vascular function and microcirculation in elderly patients.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Neuroprotective Effects of Tripeptides - Epigenetic Regulators in Mouse Model of Alzheimer's Disease
Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M, 2021, Pharmaceuticals (Basel) - Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
Khavinson V, Linkova N, Diatlova A, Trofimova S, 2021, Bulletin of Experimental Biology and Medicine - Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis
Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VKh, Dyakonov MM, Kozina LS, 2016, Advances in Gerontology - Molecular aspects of anti-atherosclerotic effects of short peptides
Khavinson VKh, Lin'kova NS, Evlashkina EV, Durnova AO, Kozlov KL, Gutop OE, 2014, Bulletin of Experimental Biology and Medicine - The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people
Kitachev KV, Sazonov AB, Kozlov KL, Petrov KIu, Sliusarev AS, Khavinson VKh, 2014, Advances in Gerontology - Short Peptides Protect Oral Stem Cells from Ageing
Sinjari B, Diomede F, Khavinson V, et al., 2020, Stem Cell Reviews and Reports - Peptides tissue-specifically stimulate cell differentiation during their aging
Khavinson VKh, Lin'kova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM, 2012, Bulletin of Experimental Biology and Medicine - Khavinson development attribution. Existing stored entry reference; Existing stored entry reference
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson specifically targeting vascular endothelial tissue. It is a fully synthetic peptide with high specificity for endothelial cells, designed to restore normal vascular cell gene expression and support angiogenesis — the formation of new blood vessels — in aging or ischemia-damaged tissue. It complements Ventfort's broader vascular coverage by focusing on endothelial cell biology specifically.